Cellipoint to Build Texas Cell Therapy Facility

Cellipont Bioservices, a contract development and manufacturing organization (CDMO) that specializes in manufacturing cell therapies, will be constructing a 76,000 square-foot commercial-ready manufacturing facility for cell therapies and gene-modified cell therapies.

Located in The Woodlands, TX, the center will feature state-of-the-art manufacturing, process development, assay development, and testing capabilities that line up with Cellipont’s 26,000 square-foot San Diego location. The building of the new facility will be completed in phases, with the first phase scheduled to begin operation in the first half of 2023.

“Cellipont is excited to move forward with this next stage of our company’s development as a best-in-class cell therapy CDMO. As our client programs advance through the clinic and toward commercialization, we are working diligently to offer them state-of-the-art facilities and capabilities,” notes Deborah Wild, Cellipont’s CEO. “This site near Houston is an ideal location to serve clients and patients across all of North America, with two major airports and a strong local workforce.”